Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers

NEJM Evidence ◽  
2021 ◽  
Author(s):  
Michael L. Wang ◽  
Jacqueline C. Barrientos ◽  
Richard R. Furman ◽  
Matthew Mei ◽  
Paul M. Barr ◽  
...  

In a phase 1 trial involving patients with refractory lymphoid cancer, an antibody-drug complex directed against ROR1 had no unexpected toxicities. About half of the patients with mantle cell lymphoma and diffuse large B-cell lymphoma had clinically meaningful responses.

2018 ◽  
Vol 37 (2) ◽  
pp. 297-306 ◽  
Author(s):  
Tycel Phillips ◽  
Paul M. Barr ◽  
Steven I. Park ◽  
Kathryn Kolibaba ◽  
Paolo F. Caimi ◽  
...  

2019 ◽  
Vol 120 (12) ◽  
pp. 1137-1146 ◽  
Author(s):  
Anke Maes ◽  
Ken Maes ◽  
Hendrik De Raeve ◽  
Eva De Smedt ◽  
Philip Vlummens ◽  
...  

2012 ◽  
Vol 61 (4) ◽  
pp. 685-693 ◽  
Author(s):  
Shih-Chuan Hsiao ◽  
Inmaculada Ribera Cortada ◽  
Luis Colomo ◽  
Hongtao Ye ◽  
Hongxiang Liu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document